BLCO

Bausch & Lomb

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Medical Instruments & Supplies

Exchange

NYSE

County of HQ

United States

Next Earnings Date

04/29/26

Business Summary

Bausch & Lomb operates in the medical instruments and supplies segment, generating revenue from specialized healthcare products where brand recognition and clinical trust matter. Its model relies on recurring demand from healthcare providers and consumers, creating steady sales flows when execution is disciplined. The moat is built on product portfolio breadth, distribution reach, and embedded relationships within clinical settings. Cash generation ultimately depends on maintaining pricing power and driving volume through differentiated medical solutions while controlling manufacturing and operating costs.

VALUATION

P/E

-

Market Cap ($M USD)

$5,834

Forward P/E

15.4

PEG

-

PRICE TO SALES

1.1

PRICE TO BOOK

0.9

EV / EBITDA

27.9

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.02

Next Year EPS Growth Estimate

$1.07

Next Year Revenue Growth Estimate

5.70%

Return on Equity (ROE)

-5.60%

Operating Margin

3.70%

Debt-to-Equity

0.8

Piotroski F-Score

5

Altman Z-Score

1.1

Return on Invested Capital (ROIC)

-0.10%%

Current Ratio

1.6

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At 0.9x Price/Book and 1.1x Price/Sales, the market is clearly discounting this business, but the discount is not irrational. A Forward P/E of 15.4 would normally imply moderate growth at a reasonable price, yet the Altman Z-Score of 1.1 signals financial distress risk and materially weak balance sheet safety. Operating Margin of -5.60% and ROIC of -0.10% confirm that capital is not being deployed efficiently, and Debt/Equity of 3.70% further compresses flexibility. This is not a clean GARP setup; it is a leveraged turnaround priced as a cautious recovery story rather than a high-confidence compounder.

AI Exposure / Tech Reliance

As a Medical Instruments & Supplies company within Healthcare, BLCO operates in a sector where product innovation and technology integration are constant. The industry benefits from procedural demand and product upgrades, which can incorporate AI-driven diagnostics and precision enhancements. However, financial strain limits how aggressively the company can invest in next-generation capabilities relative to stronger peers.

The Bull Case

A value-oriented investor could argue that 0.9x Book and 1.1x Sales already price in significant pessimism, creating asymmetric upside if margins normalize. The Piotroski F-Score of 5 indicates middling but not catastrophic financial quality, and a Current Ratio of 1.6 suggests near-term liquidity is manageable. Return on Equity at 5.70% shows the business is at least generating some equity returns despite negative operating margins, implying potential operating leverage if cost structure improves. With a Forward P/E of 15.4, even modest earnings stabilization could rerate the stock meaningfully from distressed valuation levels.

The Bear Case

The balance sheet is the central problem. A Debt/Equity ratio of 3.70% combined with an Altman Z-Score of 1.1 puts the company in the distress zone, and negative Operating Margin of -5.60% means leverage is working against equity holders. ROIC at -0.10% signals value destruction, not creation, and the absence of meaningful dividend support removes downside cushioning. With EPS Next Year estimated at -$1.02, forward earnings visibility is deteriorating, making the 15.4 Forward P/E look potentially misleading if projections compress further.

Market Sentiment & Smart Money

Short Interest %

9.30%

Analyst Consensus

2.57

Average Analyst Price Target

$18.33

Institutional Ownership %

11.50%

1-Year Beta

1.38

Insider Buying % (6 Mo)

87.60%%

Distance to 52-Week High

87.20%%

Distance to 52-Week Low

157.80%%